NCT06954480
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06954480
Title Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer (DIAMOND)
Acronym DIAMOND
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Queen Mary University of London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.